CS
RAPT

Credit Suisse’s RAPT Therapeutics RAPT Stock Holding History

Credit Suisse’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$336K Buy
4,682
+4
+0.1% +$556 ﹤0.01% 2789
2023
Q4 		$930K Buy
4,678
+448
+11% +$55.5K ﹤0.01% 2375
2023
Q3 		$562K Sell
4,230
-647
-13% -$106K ﹤0.01% 2615
2023
Q2 		$730K Buy
4,877
+96
+2% +$15K ﹤0.01% 2589
2023
Q1 		$702K Buy
4,781
+596
+14% +$121K ﹤0.01% 2538
2022
Q4 		$663K Buy
4,185
+1,773
+74% +$284K ﹤0.01% 2604
2022
Q3 		$463K Buy
2,412
+618
+34% +$117K ﹤0.01% 2832
2022
Q2 		$261K Buy
1,794
+202
+13% +$26.9K ﹤0.01% 3227
2022
Q1 		$280K Buy
1,592
+108
+7% +$20.4K ﹤0.01% 3253
2021
Q4 		$436K Buy
1,484
+49
+3% +$13.1K ﹤0.01% 3916
2021
Q3 		$357K Buy
1,435
+264
+23% +$69.8K ﹤0.01% 4015
2021
Q2 		$297K Sell
1,171
-136
-10% -$25.4K ﹤0.01% 4114
2021
Q1 		$231K Buy
1,307
+8
+0.6% +$1.32K ﹤0.01% 4081
2020
Q4 		$205K Buy
+1,299
New +$282K ﹤0.01% 4092

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Credit Suisse's RAPT Position: Q1 2024 in Review

Credit Suisse increased its RAPT Therapeutics (RAPT) stake by 0.09% in Q1 2024, buying an estimated $556 and bringing the position to 4,682 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

Credit Suisse first reported a position in RAPT in Q4 2020 and has held it in 14 quarters since. The position peaked at $930K in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • Credit Suisse held 4,682 shares of RAPT Therapeutics worth $336K as of Q1 2024.
  • Credit Suisse bought 4 RAPT Therapeutics shares in Q1 2024, an estimated $556.
  • RAPT Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2789 holding.
  • Credit Suisse first reported a position in RAPT Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Credit Suisse's RAPT Therapeutics position peaked at $930K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.